一分钟看懂
这是一项关于小细胞肺癌的II 期研究，登记的药物或干预包括Tafolecimab；Sintilimab (approved)；Etoposide；Carboplatin / Cisplatin，当前状态为招募中。登记地点显示中国长沙、济南、杭州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Tafolecimab；Sintilimab (approved)；Etoposide；Carboplatin / Cisplatin · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University · 长沙
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science · 济南
- Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences · 杭州
- First Affiliated Hospital, School of Medicine, Zhejiang University · 杭州
- Second Affiliated Hospital, School of Medicine, Zhejiang University · 杭州
公开的入选条件
- * Age ≥18 years, ECOG performance status 0-1;
- * Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) according to Veterans Administration Lung Study Group criteria;
- * Previously not receiving systemic treatment for ES-SCLC;
- * Greater than or equal to 1 measurable lesion exists according to RECIST v1.1;
- * Expected survival \>= 12 weeks;
- * Adequate organ system functions (no blood transfusion or component blood use within 14 days before testing).
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07061535；登记信息更新于 2026-09-15。